EMA accepts marketing authorization application for AVT23, a proposed biosimilar to Xolair: London, UK Tuesday, October 7, 2025, 16:00 Hrs [IST] Advanz Pharma Holdco Limited (Adva ...

Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest ...

Northland Securities analyst Carl Byrnes reiterated a Buy rating on Alvotech today and set a price target of $28.00. The company’s shares closed yesterday at $8.40. Take advantage of TipRanks Premium ...

Alvotech ( ($ALVO) ) just unveiled an announcement. On October 6, 2025, Alvotech announced that the European Medicines Agency accepted a Marketing ...

Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on ...

Alvotech (NasdaqGM:ALVO) has caught some attention in the biotech space recently, especially given its stock movement over the past month. With a 3% increase in that period, investors are wondering ...

AVT06, a promising biosimilar to aflibercept (Eylea), shows comparable efficacy and safety for treating neovascular ...

The pharmaceutical sector has seen a flurry of new deals, partnerships, and drug launches this week, presenting potential ...

Alvotech (ALVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...

ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.

Investing.com -- Alvotech (IC:ALVO) was upgraded to "buy" from "hold" by analyst Niall Alexander from Deutsche Bank Research, who kept the price target unchanged at $14. The company’s shares last ...

Investing.com -- Deutsche Bank struck a more upbeat tone on European pharmaceuticals, upgrading Alvotech to Buy from Hold while keeping its price target at $14. Shares in Alvotech rose 4.6% in U.S.